Studies in transgenic mice provided evidence that JAK2V617F and neomorphic IDH1-IDH2 mutations cooperate in vivo to drive an aggressive myeloproliferative disease; the combined mutation MP disease was characterized by an expanded pool of pathological stem/progenitor cells [75]. This evidence concerns the gene IDH2 and myeloproliferative disorder.